Joyce Y Huang1,2, Lesley M Butler3,4, Øivind Midttun5, Woon-Puay Koh6,7, Per M Ueland8,9, Renwei Wang1, Aizhen Jin10, Yu-Tang Gao11, Jian-Min Yuan1,2. 1. Division of Cancer Control and Population Science, University of Pittsburgh Cancer Institute, UPMC Cancer Pavilion, 5150 Centre Avenue - Suite 4C, Pittsburgh, PA, 15232, USA. 2. Department of Epidemiology, University of Pittsburgh, Pittsburgh, PA, USA. 3. Division of Cancer Control and Population Science, University of Pittsburgh Cancer Institute, UPMC Cancer Pavilion, 5150 Centre Avenue - Suite 4C, Pittsburgh, PA, 15232, USA. butlerl3@upmc.edu. 4. Department of Epidemiology, University of Pittsburgh, Pittsburgh, PA, USA. butlerl3@upmc.edu. 5. Bevital A/S, Bergen, Norway. 6. Duke-NUS Medical School, National University of Singapore, Singapore, Singapore. 7. Saw Swee Hock School of Public Health, National University of Singapore, Singapore, Singapore. 8. Department of Clinical Science, University of Bergen, Bergen, Norway. 9. Laboratory of Clinical Biochemistry, Haukeland University Hospital, Bergen, Norway. 10. National Registry of Diseases Office, Health Promotion Board, Singapore, Singapore. 11. Shanghai Jiaotong University, Shanghai, China.
Abstract
BACKGROUND: Vitamin B6 is an important enzymatic cofactor in pathways relevant for the development of pancreatic cancer. In order to evaluate vitamin B6 as a preventive factor for pancreatic cancer, a biomarker approach is needed to overcome the limitations inherent in self-reported dietary information. METHODS: To determine whether levels of serum B6 vitamers, including pyridoxal 5'-phosphate (PLP), pyridoxal (PL), 4-pyridoxic acid (PA), and the PA/(PLP + PL) ratio (PAr), were associated with risk of pancreatic cancer, two nested case-control studies of 187 incident pancreatic cancer cases and 258 individually matched controls were conducted within two prospective cohorts of 81,501 participants in Shanghai, China, and Singapore. PLP, PL, and PA were quantified in pre-diagnostic serum samples. Odds ratios and 95% confidence intervals (CIs) were calculated using conditional logistic regression with adjustment for potential confounders. RESULTS: The median (5th-95th percentiles) concentrations of serum PLP among control subjects of the Shanghai and Singapore cohorts were 25.7 (10.0-91.7) nmol/L and 58.1 (20.8-563.0) nmol/L, respectively. In pooled analyses, high serum PLP was associated with a reduced risk of pancreatic cancer (P for trend = 0.048); the adjusted odds ratio for the highest category of PLP (>52.4 nmol/L) was 0.46 (95% CI 0.23, 0.92) compared to vitamin B6 deficiency (<20 nmol/L). No associations were found for serum PL, PA, or PAr with pancreatic cancer risk. CONCLUSIONS: Higher concentrations of PLP may protect against the development of pancreatic cancer. The protective effect may be more apparent in populations with low concentrations of circulating vitamin B6.
BACKGROUND:Vitamin B6 is an important enzymatic cofactor in pathways relevant for the development of pancreatic cancer. In order to evaluate vitamin B6 as a preventive factor for pancreatic cancer, a biomarker approach is needed to overcome the limitations inherent in self-reported dietary information. METHODS: To determine whether levels of serum B6 vitamers, including pyridoxal 5'-phosphate (PLP), pyridoxal (PL), 4-pyridoxic acid (PA), and the PA/(PLP + PL) ratio (PAr), were associated with risk of pancreatic cancer, two nested case-control studies of 187 incident pancreatic cancer cases and 258 individually matched controls were conducted within two prospective cohorts of 81,501 participants in Shanghai, China, and Singapore. PLP, PL, and PA were quantified in pre-diagnostic serum samples. Odds ratios and 95% confidence intervals (CIs) were calculated using conditional logistic regression with adjustment for potential confounders. RESULTS: The median (5th-95th percentiles) concentrations of serum PLP among control subjects of the Shanghai and Singapore cohorts were 25.7 (10.0-91.7) nmol/L and 58.1 (20.8-563.0) nmol/L, respectively. In pooled analyses, high serum PLP was associated with a reduced risk of pancreatic cancer (P for trend = 0.048); the adjusted odds ratio for the highest category of PLP (>52.4 nmol/L) was 0.46 (95% CI 0.23, 0.92) compared to vitamin B6 deficiency (<20 nmol/L). No associations were found for serum PL, PA, or PAr with pancreatic cancer risk. CONCLUSIONS: Higher concentrations of PLP may protect against the development of pancreatic cancer. The protective effect may be more apparent in populations with low concentrations of circulating vitamin B6.
Authors: Shannon M Lynch; Alina Vrieling; Jay H Lubin; Peter Kraft; Julie B Mendelsohn; Patricia Hartge; Federico Canzian; Emily Steplowski; Alan A Arslan; Myron Gross; Kathy Helzlsouer; Eric J Jacobs; Andrea LaCroix; Gloria Petersen; Wei Zheng; Demetrius Albanes; Laufey Amundadottir; Sheila A Bingham; Paolo Boffetta; Marie-Christine Boutron-Ruault; Stephen J Chanock; Sandra Clipp; Robert N Hoover; Kevin Jacobs; Karen C Johnson; Charles Kooperberg; Juhua Luo; Catherine Messina; Domenico Palli; Alpa V Patel; Elio Riboli; Xiao-Ou Shu; Laudina Rodriguez Suarez; Gilles Thomas; Anne Tjønneland; Geoffrey S Tobias; Elissa Tong; Dimitrios Trichopoulos; Jarmo Virtamo; Weimin Ye; Kai Yu; Anne Zeleniuch-Jacquette; H Bas Bueno-de-Mesquita; Rachael Z Stolzenberg-Solomon Journal: Am J Epidemiol Date: 2009-06-26 Impact factor: 4.897
Authors: Andrew O Odegaard; Mark A Pereira; Woon-Puay Koh; Kazuko Arakawa; Hin-Peng Lee; Mimi C Yu Journal: Am J Clin Nutr Date: 2008-10 Impact factor: 7.045
Authors: Jacques Ferlay; Isabelle Soerjomataram; Rajesh Dikshit; Sultan Eser; Colin Mathers; Marise Rebelo; Donald Maxwell Parkin; David Forman; Freddie Bray Journal: Int J Cancer Date: 2014-10-09 Impact factor: 7.396
Authors: Sascha Venturelli; Christian Leischner; Thomas Helling; Markus Burkard; Luigi Marongiu Journal: Nutrients Date: 2021-11-01 Impact factor: 5.717